AstraZeneca files lawsuit against FDA regarding quetiapine

Wednesday, March 14, 2012 09:56 AM

AstraZeneca has filed a lawsuit against the FDA in district court to overturn the FDA’s denial on March 7, 2012, of citizen petitions filed by AstraZeneca with regard to Seroquel tablets and Seroquel XR extended release tablets (quetiapine fumarate).

In the citizen petitions, AstraZeneca requested the FDA withhold finally approving any generic quetiapine product that omits from its labeling certain hyperglycaemia and suicidal warning language that the FDA required AstraZeneca to include in the labeling for its own Seroquel products. Data associated with the hyperglycaemia warning language at issue is protected by marketing exclusivity periods expiring as late as December 2, 2012. AstraZeneca also raised issues regarding data exclusivity rights granted to innovative companies that conduct new clinical trials.

AstraZeneca seeks an injunction barring the FDA from granting final marketing approval of generic quetiapine until December 2, 2012, when regulatory exclusivity expires on important clinical trial data, or, alternatively, at least until a federal court has a meaningful opportunity to review imminent FDA action regarding the pending generic marketing applications.

AstraZeneca said it will “vigorously defend its legal rights.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs